| Followers | 13 |
| Posts | 1365 |
| Boards Moderated | 0 |
| Alias Born | 05/05/2006 |
Thursday, June 08, 2006 4:45:40 PM
north40000 - question - I know that patent law is unique but in this case, does a legal presumption work in INSM's favor?
[For the layman here - a legal presumption is a truth that the law assumes ex. "a properly posted letter reached its intended destination" Legal presumtions works to shift the burden of proof to the person who did not receive the letter to offer evidence that the letter did not reach its destination]
Now in this case the US Patent Office issued the LATER patents upon which Iplex could be developed and produced. Isn't there a presumption that the US Patent Office WOULD NOT have issued the patents that would infringe upon prior patents given to DNA, one as I recall many years before. The same with Iplex - it was given orphan status as a different drug than Increlex so the presumption would be IPlex is not a generic but something different. Consequently, INSM should be able to rely upon the patents issues to it in developing and manufacturing Iplex, a unique drug.
Now we know as Plaintiffs, DNA and TRCA, carry the burden of proof anyway, but would the legal presumptions and reasonable reliance factors strengthen INSM's defenses? I know that abharp ...believe it does not because both parties can plead "legal presumption" but in my view, the legal presumption would only apply to the patents issued later. Thanks
[For the layman here - a legal presumption is a truth that the law assumes ex. "a properly posted letter reached its intended destination" Legal presumtions works to shift the burden of proof to the person who did not receive the letter to offer evidence that the letter did not reach its destination]
Now in this case the US Patent Office issued the LATER patents upon which Iplex could be developed and produced. Isn't there a presumption that the US Patent Office WOULD NOT have issued the patents that would infringe upon prior patents given to DNA, one as I recall many years before. The same with Iplex - it was given orphan status as a different drug than Increlex so the presumption would be IPlex is not a generic but something different. Consequently, INSM should be able to rely upon the patents issues to it in developing and manufacturing Iplex, a unique drug.
Now we know as Plaintiffs, DNA and TRCA, carry the burden of proof anyway, but would the legal presumptions and reasonable reliance factors strengthen INSM's defenses? I know that abharp ...believe it does not because both parties can plead "legal presumption" but in my view, the legal presumption would only apply to the patents issued later. Thanks
Recent INSM News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2026 08:43:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/16/2026 08:17:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:41:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 08:01:21 PM
- Insmed Provides Clinical Update on Phase 2b CEDAR Study • PR Newswire (US) • 04/07/2026 08:01:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/06/2026 08:42:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:07:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 09:10:46 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/01/2026 08:03:54 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/01/2026 08:02:49 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/01/2026 08:01:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 08:13:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/30/2026 09:31:03 PM
- Insmed shares rise after UTHR trial data and Morgan Stanley upgrade • IH Market News • 03/30/2026 03:04:13 PM
- Insmed shares rise on positive results from ARIKAYCE Phase 3b study • IH Market News • 03/23/2026 02:34:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 11:00:30 AM
- Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease • PR Newswire (US) • 03/23/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:05:20 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/19/2026 08:57:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2026 09:59:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:16:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:15:10 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 03/05/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:14:51 PM
